You are here: Industry Insights > Dacomitinib

News List

Research identifies nine potential new COVID-19 treatments expresspharma
April 06, 2021
Three already have FDA approval — the transplant-rejection drug cyclosporine, the cancer drug dacomitinib, and the antibiotic salinomycin.
NICE endorses dacomitinib for treatment of lung cancer europeanpharmaceuticalreview
July 09, 2019
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
US green light for Pfizer’s lung cancer drug pharmatimes
September 29, 2018
Pfizer’s pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib has been approved in the US as a treatment for some forms of lung cancer.
Pfizer files lung cancer drug in the EU, US pharmatimes
July 18, 2018
Pfizer has filed its pan-human epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor dacomitinib on both sides of the Atlantic for a particular form of lung cancer.
FDA, European Medicines Agency Accept Regulatory Submissions for Review of Dacomitinib americanpharmaceuticalreview
April 09, 2018
Pfizer Announces U.S. Food and Drug Administration (FDA) Accepts New Drug Application from the Company and Approves Priority Review of Damotinib